FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3130275892> ?p ?o ?g. }

• W3130275892 endingPage "02" @default.
• W3130275892 startingPage "OT" @default.
• W3130275892 abstract "Abstract Background AZD9833 is a next-generation oral selective estrogen receptor (ER) antagonist and degrader (SERD) that has shown anti-tumor efficacy in a range of pre-clinical xenograft models of breast cancer. The first-in-human study, assessing AZD9833 as a monotherapy and in combination with palbociclib (SERENA-1; NCT03616587), established a dose-dependent safety profile with clinical benefit and target engagement in pre- and post-menopausal women at all dose levels. Here, we describe the design of SERENA-2, a Phase 2 randomized, open-label trial of three different doses of AZD9833 versus fulvestrant. Methods SERENA-2 is a global comparative study of three different doses of AZD9833 versus fulvestrant in post-menopausal women with advanced ER+, HER2− breast cancer with disease recurrence or progression after ≥1 endocrine therapy. The study will evaluate the efficacy and safety of AZD9833 monotherapy once daily at three dose levels, versus fulvestrant monotherapy administered according to its label. Eligible patients will have received no prior fulvestrant or other oral SERD, and no more than one endocrine therapy and one chemotherapy in the advanced setting. Prior treatment with CDK4/6 inhibitors is permitted. Patients will be randomized 1:1:1:1 to one of four treatment groups: AZD9833 75 mg, 150 mg, 300 mg, or fulvestrant. The primary objective of the study is to determine the clinical efficacy of AZD9833 as assessed by progression-free survival, compared with fulvestrant. Secondary objectives include objective response rate, duration of response, percentage change in tumor size at 16 weeks, clinical benefit rate at 24 weeks, and overall survival. Pharmacokinetics, pharmacodynamic biomarker changes from baseline, and effects of AZD9833 and fulvestrant on patients’ health-related quality of life will also be assessed. Exploratory endpoints include predictive markers of response and/or acquired resistance to AZD9833 and fulvestrant, including circulating tumor DNA mutation profiling and dynamics, circulating tumor cell enumeration, and analysis of tumor samples. Patient enrollment commenced in Q2 2020, with a target enrollment of 288 patients across approximately 100 sites in up to 17 countries. Efficacy analyses will compare each dose of AZD9833 with fulvestrant. Sample size was calculated to provide 80% power for the primary endpoint. The primary analysis will use a Cox proportional hazards model stratified by prior use of CDK4/6 inhibitors and presence of lung and/or liver metastases to compare progression-free survival in each dose of AZD9833 versus fulvestrant. Another randomized, open-label, parallel-group, pre-surgical study investigating the biological effects of AZD9833 in ER+, HER2− primary breast cancer (SERENA-3) is also ongoing. For more information please contact Dr Mafalda Oliveira at: moliveira@vhio.net. Citation Format: Mafalda Oliveira, Maxine Bennett, Ali Khalil, Richard Mather, Rhiannon Maudsley, Sam McGuinness, Christopher J Morrow, Andy Sykes, Li Zhang, Teresa Klinowska, Justin PO Lindemann, Danielle Carroll. A randomized, open-label, parallel-group, multicenter phase 2 study comparing the efficacy and safety of oral AZD9833 versus fulvestrant in women with advanced ER-positive HER2-negative breast cancer (SERENA-2) [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr OT-09-02." @default.
• W3130275892 created "2021-03-01" @default.
• W3130275892 creator A5018607590 @default.
• W3130275892 creator A5026287875 @default.
• W3130275892 creator A5026506069 @default.
• W3130275892 creator A5037930894 @default.
• W3130275892 creator A5046534481 @default.
• W3130275892 creator A5046909219 @default.
• W3130275892 creator A5051591924 @default.
• W3130275892 creator A5053983312 @default.
• W3130275892 creator A5059691963 @default.
• W3130275892 creator A5066683906 @default.
• W3130275892 creator A5066716873 @default.
• W3130275892 creator A5071204980 @default.
• W3130275892 date "2021-02-15" @default.
• W3130275892 modified "2023-09-27" @default.
• W3130275892 title "Abstract OT-09-02: A randomized, open-label, parallel-group, multicenter phase 2 study comparing the efficacy and safety of oral AZD9833 versus fulvestrant in women with advanced ER-positive HER2-negative breast cancer (SERENA-2)" @default.
• W3130275892 doi "https://doi.org/10.1158/1538-7445.sabcs20-ot-09-02" @default.
• W3130275892 hasPublicationYear "2021" @default.
• W3130275892 type Work @default.
• W3130275892 sameAs 3130275892 @default.
• W3130275892 citedByCount "1" @default.
• W3130275892 countsByYear W31302758922023 @default.
• W3130275892 crossrefType "journal-article" @default.
• W3130275892 hasAuthorship W3130275892A5018607590 @default.
• W3130275892 hasAuthorship W3130275892A5026287875 @default.
• W3130275892 hasAuthorship W3130275892A5026506069 @default.
• W3130275892 hasAuthorship W3130275892A5037930894 @default.
• W3130275892 hasAuthorship W3130275892A5046534481 @default.
• W3130275892 hasAuthorship W3130275892A5046909219 @default.
• W3130275892 hasAuthorship W3130275892A5051591924 @default.
• W3130275892 hasAuthorship W3130275892A5053983312 @default.
• W3130275892 hasAuthorship W3130275892A5059691963 @default.
• W3130275892 hasAuthorship W3130275892A5066683906 @default.
• W3130275892 hasAuthorship W3130275892A5066716873 @default.
• W3130275892 hasAuthorship W3130275892A5071204980 @default.
• W3130275892 hasConcept C121608353 @default.
• W3130275892 hasConcept C126322002 @default.
• W3130275892 hasConcept C143998085 @default.
• W3130275892 hasConcept C168563851 @default.
• W3130275892 hasConcept C197934379 @default.
• W3130275892 hasConcept C2775930923 @default.
• W3130275892 hasConcept C2776999253 @default.
• W3130275892 hasConcept C2779744173 @default.
• W3130275892 hasConcept C2780482068 @default.
• W3130275892 hasConcept C530470458 @default.
• W3130275892 hasConcept C535046627 @default.
• W3130275892 hasConcept C71924100 @default.
• W3130275892 hasConcept C84606932 @default.
• W3130275892 hasConceptScore W3130275892C121608353 @default.
• W3130275892 hasConceptScore W3130275892C126322002 @default.
• W3130275892 hasConceptScore W3130275892C143998085 @default.
• W3130275892 hasConceptScore W3130275892C168563851 @default.
• W3130275892 hasConceptScore W3130275892C197934379 @default.
• W3130275892 hasConceptScore W3130275892C2775930923 @default.
• W3130275892 hasConceptScore W3130275892C2776999253 @default.
• W3130275892 hasConceptScore W3130275892C2779744173 @default.
• W3130275892 hasConceptScore W3130275892C2780482068 @default.
• W3130275892 hasConceptScore W3130275892C530470458 @default.
• W3130275892 hasConceptScore W3130275892C535046627 @default.
• W3130275892 hasConceptScore W3130275892C71924100 @default.
• W3130275892 hasConceptScore W3130275892C84606932 @default.
• W3130275892 hasIssue "4_Supplement" @default.
• W3130275892 hasLocation W31302758921 @default.
• W3130275892 hasOpenAccess W3130275892 @default.
• W3130275892 hasPrimaryLocation W31302758921 @default.
• W3130275892 hasRelatedWork W2135944809 @default.
• W3130275892 hasRelatedWork W2754339892 @default.
• W3130275892 hasRelatedWork W2931385471 @default.
• W3130275892 hasRelatedWork W3083148719 @default.
• W3130275892 hasRelatedWork W3093743109 @default.
• W3130275892 hasRelatedWork W3203690439 @default.
• W3130275892 hasRelatedWork W4206711305 @default.
• W3130275892 hasRelatedWork W4248789801 @default.
• W3130275892 hasRelatedWork W4322772104 @default.
• W3130275892 hasRelatedWork W4322774115 @default.
• W3130275892 hasVolume "81" @default.
• W3130275892 isParatext "false" @default.
• W3130275892 isRetracted "false" @default.
• W3130275892 magId "3130275892" @default.
• W3130275892 workType "article" @default.